IN8bio Dirección

Dirección controles de criterios 3/4

IN8bio's El consejero delegado es William Ho , nombrado en Nov 2015, tiene un mandato de 8.08 años. la remuneración anual total es $1.73M , compuesta por 31.8% salario y 68.2% primas, incluidas acciones y opciones de la empresa. posee directamente 8.11% de las acciones de la empresa, por valor de $3.32M . La antigüedad media del equipo directivo y del consejo de administración es de 3 años y 3.3 años respectivamente.

Información clave

William Ho

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO	31.8%
Permanencia del CEO	8.4yrs
Participación del CEO	7.2%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de William Ho en comparación con los beneficios de IN8bio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$30m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$2m	US$550k	-US$29m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	-US$18m
Dec 31 2021	US$2m	US$446k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$1m	US$279k	-US$10m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$214k	US$214k	-US$6m

Compensación vs. Mercado: William($USD1.73M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de William ha sido consistente con los resultados de la empresa en el último año.

CEO

William Ho (46 yo)

8.4yrs

Permanencia

US$1,729,646

Compensación

Mr. William Ho, also known as Will, is the Co-Founder of IN8bio, Inc. and has been President, Chief Executive Officer and Director since November 2015 and had been its Chief Financial Officer since October...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tai-Wei Ho	Co-Founder	8.4yrs	US$1.73m	7.22% $ 3.5m
Kate Rochlin	Chief Operating Officer	3.3yrs	US$934.68k	0.041% $ 19.5k
Trishna Goswami	Chief Medical Officer	2.4yrs	US$999.31k	0.016% $ 7.5k
Lawrence Lamb	Executive VP	5.4yrs	US$918.75k	0.23% $ 112.5k
Patrick McCall	CFO & Secretary	3.2yrs	US$1.55m	0.062% $ 29.7k
Michael McNamara	Vice President of Accounting	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

45yo

Promedio de edad

Equipo directivo experimentado: INABEl equipo directivo de la empresa se considera experimentado (3 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tai-Wei Ho	Co-Founder	8.4yrs	US$1.73m	7.22% $ 3.5m
Peter Brandt	Independent Director	4.7yrs	US$83.18k	0.85% $ 410.4k
Alan Roemer	Independent Chairman of the Board	3.6yrs	US$144.18k	0.37% $ 175.9k
Emily Fairbairn	Independent Director	2.8yrs	US$60.68k	7.44% $ 3.6m
Marcela Maus	Member of Scientific Advisory Board	no data	sin datos	sin datos
Travis Whitfill	Independent Director	3.6yrs	US$73.68k	0% $ 0
Luba Greenwood	Independent Director	2.8yrs	US$69.18k	0.018% $ 8.7k
Bruce Levine	Member of Scientific Advisory Board	no data	sin datos	sin datos
Siraj Ali	Member of Scientific Advisory Board	no data	sin datos	sin datos
Bianca Santomasso	Member of Scientific Advisory Board	no data	sin datos	sin datos
Dieter Kabelitz	Member of Scientific Advisory board	no data	sin datos	sin datos
Michael Bishop	Member of Scientific Advisory Board	1.6yrs	sin datos	sin datos

3.6yrs

Permanencia media

46yo

Promedio de edad

Junta con experiencia: La junta directiva de INAB se considera experimentada (3.3 años de antigüedad promedio).

IN8bio Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

Independent Director recently bought US$200k worth of stock

Recent updates

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

New major risk - Financial position

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

New major risk - Shareholder dilution

Price target decreased by 16% to US$11.00

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Price target decreased to US$9.67

High number of new and inexperienced directors

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

IN8bio gains 53% as H.C. Wainwright initiates with Buy

Independent Director recently bought US$200k worth of stock

IN8bio raises additional funds from underwriter of stock offering

IN8bio prices $10.25M stock offering

IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100

IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development

IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc., Annual General Meeting, Jun 01, 2022

IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100

IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans

IN8bio, Inc. Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

In8bio Provides Update from the Ongoing Phase 1 Clinical Trial of Its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

Director recently bought US$1.0m worth of stock

IPO Update: IN8bio Aims For Downsized IPO

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad